The Drug Discovery Services Market Report 2022-2032: This report will prove invaluable to leading firms striving for new revenue pockets if they wish to better understand the industry and its underlying dynamics. It will be useful for companies that would like to expand into different industries or to expand their existing operations in a new region.
Additionally, COVID-19 offers a chance for the provider of drug discovery services to take on a larger role in healthcare. Over the course of the forecast period, new revenue opportunities for market players are anticipated to be created by the rising number of coronavirus cases around the world and the expanding interaction between technology and healthcare.
Services Market, 2022 to 2032, with a focus on this segment of these companies’ operations.
Rising Prevalence of Chronic Diseases to Boost Market Growth Through 2032
The market for drug discovery services is expected to expand due to the rising disease burden in emerging nations, which includes several Middle Eastern and African nations as well as Asia-Pacific nations. These developing nations deal with a wide range of illnesses, including skin conditions, cancer, HIV, cardiovascular, and neurological conditions. It is anticipated that applications for drug discovery services will aid in the control of these illnesses by extending the reach of treatment, assisting patients in following prescribed treatment plans and increasing public awareness of epidemics.Additionally, COVID-19 offers a chance for the provider of drug discovery services to take on a larger role in healthcare. Over the course of the forecast period, new revenue opportunities for market players are anticipated to be created by the rising number of coronavirus cases around the world and the expanding interaction between technology and healthcare.
What Questions Should You Ask before Buying a Market Research Report?
- How is the drug discovery services market evolving?
- What is driving and restraining the drug discovery services market?
- How will each drug discovery services submarket segment grow over the forecast period and how much revenue will these submarkets account for in 2032?
- How will the market shares for each drug discovery services submarket develop from 2022 to 2032?
- What will be the main driver for the overall market from 2022 to 2032?
- Will leading drug discovery services markets broadly follow the macroeconomic dynamics, or will individual national markets outperform others?
- How will the market shares of the national markets change by 2032 and which geographical region will lead the market in 2032?
- Who are the leading players and what are their prospects over the forecast period?
- How will the industry evolve during the period between 2020 and 2032? What are the implications of drug discovery services projects taking place now and over the next 10 years?
- Is there a greater need for product commercialisation to further scale the drug discovery services market?
- Where is the drug discovery services market heading and how can you ensure you are at the forefront of the market?
- What are the best investment options for new product and service lines?
- What are the key prospects for moving companies into a new growth path and C-suite?
You need to discover how this will impact the drug discovery services market today, and over the next 10 years:
- Our 689-page report provides 259 tables and 493 charts/graphs exclusively to you.
- The report highlights key lucrative areas in the industry so you can target them - NOW.
- It contains in-depth analysis of global, regional and national sales and growth.
- It highlights for you the key successful trends, changes and revenue projections made by your competitors.
Forecasts to 2032 and other analyses reveal commercial prospects
- In addition to revenue forecasting to 2032, the new study provides you with recent results, growth rates, and market shares.
- You will find original analyses, with business outlooks and developments.
- Discover qualitative analyses (including market dynamics, drivers, opportunities, restraints and challenges), cost structure, impact of rising drug discovery services prices and recent developments.
Segments Covered in the Report
Services Type Outlook
- Chemistry Services
- Drug Metabolism and Pharmacokinetics (DMPK)
- Biology Services
Process
- Hit to Lead Identification
- Lead Optimization
- Target Selection
- Target Validation
- Candidate Validation
Drug Type
- Small Molecules
- Biologics
Therapeutic Area
- Oncology
- Neurology
- Infectious and Immune System Diseases
- Cardiovascular Diseases
- Respiratory Diseases
- Digestive System Diseases
- Other Therapeutic Areas
Technology
- High Throughput Screening
- Biochips
- Nanotechnology
- Spectroscopy
- Pharmacogenomics and Pharmacogenetics
- Others
End-user
- Pharmaceutical and Biotechnology Companies
- Academic and Research Institutes
- Others
North America
- U.S.
- Canada
Europe
- Germany
- Spain
- United Kingdom
- France
- Italy
- Rest of Europe
Asia Pacific
- China
- Japan
- India
- Australia
- South Korea
- Southeast Asia
- Rest of Asia Pacific
Latin America
- Brazil
- Argentina
- Mexico
- Colombia
- Rest of Latin America
MEA
- GCC
- South Africa
- Rest of MEA
Services Market, 2022 to 2032, with a focus on this segment of these companies’ operations.
Leading companies and the potential for market growth
- BioBlocks, Inc
- Charles River Laboratories
- Domainex
- Eurofins Scientific
- Evotec
- Jubilant Pharmova Limited Company
- Labcorp Drug Development (Parent Company Laboratory Corporation of America Holdings)
- Thermo Fisher Scientific Inc.
- Sygnature Discovery
- WuXi AppTec
How will the Drug Discovery Services Market, 2022 to 2032 report help you?
In summary, this 680+ page report provides you with the following knowledge:- Revenue forecasts to 2032 for Drug Discovery Services Market, 2022 to 2032 Market, with forecasts for service type, process, drug type, therapeutic area, technology, and end-user each forecast at a global and regional level - discover the industry’s prospects, finding the most lucrative places for investments and revenues.
- Revenue forecasts to 2032 for four regional and 23 key national markets - See forecasts for the Drug Discovery Services Market, 2022 to 2032 market in North America, Europe, Asia-Pacific, Latin America and MEA. Also forecasted is the market in the US, Canada, Mexico, Brazil, Germany, France, UK, Italy, China, India, Japan, and Australia among other prominent economies.
- Prospects for established firms and those seeking to enter the market - including company profiles for 10 of the major companies involved in the Drug Discovery Services Market, 2022 to 2032.
Information found nowhere else
With this new report, you are less likely to fall behind in knowledge or miss out on opportunities. See how this work could benefit your research, analyses, and decisions. The study is for everybody needing commercial analyses for the drug discovery services market, 2022 to 2032, market-leading companies. You will find data, trends and predictions.Table of Contents
1 Report Overview
3 Premium Insights
4 Market Overview
5 Global Drug Discovery Services Market Analysis by Services Type
6 Global Drug Discovery Services Market Analysis by Process
7 Global Drug Discovery Services Market Analysis by Drug Type
8 Global Drug Discovery Services Market Analysis by Therapeutic Area
9 Global Drug Discovery Services Market Analysis by Technology
10 Global Drug Discovery Services Market Analysis by End User
11 Global Drug Discovery Services Market Analysis by Region
12 North America Drug Discovery Services Market Analysis
13 Europe Drug discovery services Market Analysis
14 Asia Pacific Drug discovery services Market Analysis
15 Latin America Drug discovery services Market Analysis
16 MEA Drug discovery services Market Analysis
17 Company Profiles
18 Conclusion and Recommendations
List of Tables
Companies Mentioned
- BioBlocks, Inc
- Charles River Laboratories International, Inc.
- Domainex
- Eurofins Scientific
- Evotec
- Jubilant Pharmova Limited Company
- Labcorp Drug Development (Parent Company Laboratory Corporation of America Holdings)
- Sygnature Discovery
- Thermo Fisher Scientific Inc.
- Wuxi Apptec
- Aragen Life Sciences Pvt. Ltd.
- Certara, USA
- Charnwood Molecular LTD
- ChemBridge Corporation
- Curia Global Inc.
- Drug Discovery Alliances Inc.
- Frontage Holdings Corporation
- GenScript Biotech Corporation
- Malvern Panalytical Ltd (Parent Company Spectris PLC)
- Nanosyn
- NUVISAN Pharma Holding GmbH
- Pharmaron Beijing Co., Ltd.
- Piramal Enterprises Limited
- Promega Corporation
- Selvita S.A.
- Shanghai ChemPartner Co., Ltd.
- Shanghai Medicilon Inc.
- Syngene International Limited
- Taros Chemicals GmbH & Co. KG
- TCG Lifesciences Pvt Ltd.
- Viva Biotech (Shanghai) Ltd.
- Association of British Pharmaceutical Industry (ABPI)
- Central Drugs Standard Control Organization (CDSCO)
- Department of Health and Family Welfare
- Development and Reform Commission (NDRC)
- European Commission
- European Medicines Agency (EMA)
- Food and Drug Administration (US FDA)
- Indian Drug Manufacturer's Association (IDMA)
- International Society of Pharmaceutical Engineering (IPSE)
- Korea Food and Drug Administration (KFDA)
- Korea Pharmaceutical Manufacturer's Association (KPMA)
- Medicines and Healthcare Products Regulatory Agency (MHRA)
- Medicines Manufacturing Industry Partnership (MMIP)
- Ministry of Health (MOH)
- Ministry of Health, Labor and Welfare (MHLW)
- Ministry of Industry and Information Technology (MIIT)
- Pharmaceutical and Medical Devices Agency (PMDA)
- World Health Organization (WHO)
